Search

A study presented at the 2017 annual meeting of the American Society of Clinical Oncology showed that an online tool to monitor patients’ symptoms improved overall survival.

… Sunday, June 4, 2017 Summary A new analysis showed that overall survival was improved for people who monitored their symptoms using an online tool. People receiving chemotherapy for metastatic solid tumors survived longer when they used a web-based tool to document their symptoms, according to results

Three young investigators who have taken significant steps toward advancing the understanding of cancer will be the recipients of this year's Paul Marks Prize for Cancer Research, a prize awarded biennially since 2001 to scientists under the age of forty-six by Memorial Sloan Kettering Cancer Center.

… Tuesday, September 29, 2009 Three young investigators who have taken significant steps toward advancing the understanding of cancer will be the recipients of the 2009 Paul Marks Prize for Cancer Research, a prize awarded biennially since 2001 to scientists under the age of forty-six by Memorial Sloan

Investigators have created the first-ever genetically engineered model of cancer made from human embryonic stem cells in culture.

… Monday, December 1, 2014 Summary Investigators have created the first-ever genetically engineered model of cancer made from human embryonic stem cells in culture. Since the late 1990s, when researchers first reported a technique to isolate and grow human embryonic stem cells, known as ES cells, in culture

Learn about diversity and inclusion at Memorial Sloan Kettering, as people from across MSK share their insights and personal experiences.

… Thursday, October 1, 2020 Memorial Sloan Kettering is committed to having conversations about discrimination, diversity, and inclusion, and creating change. People from across MSK share their personal experiences and insights. Louis Voigt Louis Voigt LOUIS VOIGT Associate Attending Department of Anesthesiology

An international study led by researchers at Memorial Sloan Kettering Cancer Center has identified genetic variants in women with BRCA2 mutations that may increase or decrease their risk of developing breast cancer.

… Thursday, October 28, 2010 An international study led by researchers at Memorial Sloan Kettering Cancer Center has identified genetic variants in women with BRCA2 mutations that may increase or decrease their risk of developing breast cancer . The study was published today online in the open-access journal

GSK congratulates ten of its doctoral students who have been recognized by esteemed organizations for their promising academic research.

… Thursday, October 8, 2020 The Gerstner Sloan Kettering (GSK) Graduate School of Biomedical Sciences congratulates ten of its doctoral students — eight of them women — who have been recognized by esteemed organizations for their promising academic research. They each will receive stipend awards to support

Learn about a blood test using carbon nanotubes that could potentially detect brain tumors.

… Thursday, January 8, 2026 Imagine a blood test that detects the first signs of a  brain tumor when it might be treated more easily. A liquid biopsy for brain cancers is now one step closer to reality. The laboratory of  Memorial Sloan Kettering Cancer Center (MSK) biomedical engineer Daniel Heller, PhD

Learn about how the Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center supports MSK researchers as they learn more about the number one problem in cancer research today.

… Thursday, July 1, 2021 Alan Gerry has always recognized an opportunity when he sees one. His parents both emigrated from Russia to New York City in their youth so their families could build better lives. They met while working in a garment factory on the Lower East Side and soon married and had three

Researchers have engineered a gene into therapeutic cells that allows them to turn off tumor growth if some of the cells become cancerous.

… Thursday, September 18, 2014 Summary Researchers have engineered a gene into therapeutic cells that allows them to turn off tumor growth if some of the cells become cancerous. Regenerative medicine is based on the idea that stem cells could be used to regrow other cells or tissues that have been lost

Learn more about olaratumab, a promising drug that has been shown to extend survival for people with advanced soft tissue sarcoma — particularly leiomyosarcoma — by nearly a year in a phase II clinical trial.

… Monday, June 13, 2016 Summary A phase II clinical trial for sarcoma has shown that the targeted drug therapy olaratumab extends survival by nearly a year for people with advanced disease. The study’s lead investigator says the results are “unprecedented” for this rare disease, which currently has very